This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GSK1614235, DSP-3235, KGA-3235
Description: DSP-3235 is a sodium glucose transporter-1 (SGLT-1) inhibitor.
Dainippon and Kissei
In March 2008, Dainippon licensed the drug from Kissei.
In July 2011, Dainippon discontinued its development of DSP-3235. Additionally, the Company no longer lists DSP-3235 in its pipeline. As a result, we believe the partnership between Kissei and Dainippon has been cancelled.
GlaxoSmithKline and Kissei
In June 2008, Kissei concluded an agreement with GlaxoSmithKline on the KGT compounds discovered and developed by Kissei, to grant exclusive development and sales right in Japan, South Korea, Taiwan and China.
Partners: Kissei Pharmaceutical Co., Ltd
Additional information available to subscribers only: